BridgeMD
New treatment option for Acute Ischemic Stroke
Official title Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke
ClinicalTrials.gov ID: NCT05630586
What this study is testing
What is Semaglutide?
Semaglutide is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for acute ischemic stroke.
Also referred to as Ozempic.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Can Semaglutide help reduce the damage caused by a stroke? ASSET trial is a national, multicenter, clinical trial, investigating the safety and efficacy of Semaglutide in non-diabetic patients with acute ischemic stroke.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Male and female patients (≥ 18 years) at the time of signed informed consent/proxy consent
- Acute ischemic stroke with disabling neurological deficits (defined as an impairment of one or more of the following: language, motor function...
- Onset/last seen well to randomization \< 4.5 hours
- None to moderate disability in daily living before symptom onset (pre-stroke modified Rankin Scale 0-3)
You likely can't join if
- Diabetes (known) or plasma/point of care test-glucose \>11.1 mmol/L at admission
- BMI\< 22
- History of pancreatitis, medullary thyroid carcinoma
- Predisposition or known Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Short remaining life expectancy (\< 12months) and/or severe neurodegenerative disease
- Pregnancy or planned pregnancy within 12 months or breastfeeding
See the full eligibility criteria
- Male and female patients (≥ 18 years) at the time of signed informed consent/proxy consent
- Acute ischemic stroke with disabling neurological deficits (defined as an impairment of one or more of the following: language, motor function, cognition, gaze, vision, neglect, or ataxia)
- Onset/last seen well to randomization \< 4.5 hours
- None to moderate disability in daily living before symptom onset (pre-stroke modified Rankin Scale 0-3)
- Diabetes (known) or plasma/point of care test-glucose \>11.1 mmol/L at admission
- BMI\< 22
- History of pancreatitis, medullary thyroid carcinoma
- Predisposition or known Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Short remaining life expectancy (\< 12months) and/or severe neurodegenerative disease
- Pregnancy or planned pregnancy within 12 months or breastfeeding
- Renal impairment measured as estimated glomerular filtration rate (eGFR) value of \<30 mL/min/1.73 m2
The study team makes the final eligibility decision.
Where it's taking place
- Aarhus, Denmark
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aarhus, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.